Purdue NDA For Oxycodone/Naloxone Combo Tests New FDA Policy

The sponsor believes its data package could support a labeling claim that the drug “is expected to result in a meaningful reduction in abuse”; the agency’s review could indicate the strength of data needed to support such a claim.